Join Alumis for a virtual key opinion leader (KOL) event featuring leading dermatology and psoriasis expert Dr. Andrew Blauvelt, who will join company management to discuss results from the Phase 3 ONWARD program evaluating envudeucitinib, a next generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.

Dr. Blauvelt will review 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD1 and ONWARD2 studies of envudeucitinib, including new data on skin clearance, symptoms, and quality-of-life in psoriasis.

A live question and answer session will follow the formal presentations.

_{Envudeucitinib is an investigational drug not reviewed or approved by any regulatory agency.}